Biomarkers and Pathology

One imperative part of Pathology in the assessment of bosom malignancy is biomarker testing, particularly the precise appraisal of the estrogen receptor (ER), progesterone receptor (PR), and Her2 status of a patient's bosom tumor. Biomarkers can be prognostic, prescient, or both. Prognostic biomarkers are free measures of forecast to such an extent that the nearness or nonappearance of the biomarker is connected with a patient's general clinical result (i.e., danger of repeat and mortality).

    Related Conference of Biomarkers and Pathology

    October 19-20, 2026

    6th Euro-Global Summit on Probiotics & Nutraceuticals

    Paris, France
    November 16-17, 2026

    11th Global Summit on Midwifery and Womens Health

    Tokyo, Japan
    December 16-17, 2026

    7th Global Summit on Public Health

    Amsterdam, Netherlands
    January 18-19, 2027

    44th International Conference on Womens Health

    Bangkok, Thailand
    January 18-19, 2027

    10th World Congress on PCOS and Reproductive Healthcare

    Bangkok, Thailand
    February 01-02, 2027

    9th International Conference on Digital Health

    London, UK
    February 15-16, 2027

    23rd World Congress on Healthcare & Technologies

    Paris, France
    May 17-18, 2027

    38th European Heart and Heart Failure Congress

    Paris, France
    July 26-27, 2027

    5th Global Conference on Aging and Gerontology

    Paris, France
    August 24-25, 2027

    23rd Global Biomarkers and Clinical Research Summit

    Paris, France

    Biomarkers and Pathology Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in